Royal Bank of Canada set a €65.00 ($75.58) target price on MorphoSys (ETR:MOR) in a research report released on Friday, Borsen Zeitung reports. The brokerage currently has a sell rating on the stock.
A number of other research analysts have also weighed in on the company. JPMorgan Chase & Co. set a €120.00 ($139.53) price objective on MorphoSys and gave the stock a buy rating in a report on Friday. Goldman Sachs Group set a €114.00 ($132.56) price objective on MorphoSys and gave the stock a neutral rating in a report on Friday. Berenberg Bank set a €108.00 ($125.58) price objective on MorphoSys and gave the stock a buy rating in a report on Wednesday. Deutsche Bank set a €125.00 ($145.35) price objective on MorphoSys and gave the stock a buy rating in a report on Thursday, May 9th. Finally, Independent Research set a €96.00 ($111.63) target price on MorphoSys and gave the stock a neutral rating in a research report on Thursday, May 9th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of Hold and an average price target of €100.78 ($117.18).
MOR stock traded down €0.25 ($0.29) on Friday, reaching €93.25 ($108.43). 193,141 shares of the company’s stock were exchanged, compared to its average volume of 153,687. MorphoSys has a twelve month low of €76.45 ($88.90) and a twelve month high of €124.90 ($145.23). The firm has a market capitalization of $2.94 billion and a PE ratio of -50.16. The company has a debt-to-equity ratio of 8.65, a current ratio of 7.75 and a quick ratio of 7.53.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
See Also: Balance Sheet
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.